Loading
Unresectable hepatocellular carcinoma, first line
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Tremelimumab Monoclonal antibody (anti-CTLA-4) | 300 mg single priming dose | IV | D1 | cycle 1 only |
Durvalumab Monoclonal antibody (anti-PD-L1) | 1,500 mg | IV | D1 |
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.